Cerus Corporation CERS
Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Ask Irving AI About CERS
Get to know the stock you’re researching through a simple conversation. Ask Irving about its Weiss rating, financial health, dividends, and potential risks — right from the stock page.
Get answers about this stock. Instantly.
Ask about the company’s financial health and its Weiss Safety, Reward, and Risk Ratings, with answers grounded in Weiss Ratings data.
Understand the numbers behind the rating.
Explore profits, cash flow, valuation, and dividends. Ask follow-up questions without leaving the stock page.
Put the stock’s strengths and risks in context.
Look beyond a single number. Explore rating changes and company trends to better understand the stock’s outlook.
Company Overview
Cerus Corporation is a biomedical products company focused on developing and commercializing pathogen reduction technologies for blood safety. The company operates within the healthcare, medical technology, and transfusion medicine industries, with its primary commercial platform centered on the INTERCEPT Blood System, a pathogen inactivation technology designed to reduce the risk of transfusion-transmitted infections in blood components. Cerus generates revenue primarily through sales of disposable kits, illuminators, and related support services used by blood centers, hospitals, and transfusion service providers.
The company’s core markets include blood collection organizations, national blood systems, hospitals, and healthcare agencies across North America, Europe, the Middle East, and selected Asia-Pacific markets. Cerus has positioned itself as a specialized leader in pathogen reduction technology, benefiting from regulatory approvals in multiple jurisdictions and long-term relationships with blood service operators. Founded in 1991 and headquartered in Concord, California, Cerus evolved from an early-stage biotechnology company into a commercial-stage medical technology company focused primarily on blood safety and transfusion support infrastructure.
Business Operations
Cerus conducts operations primarily through the commercialization of the INTERCEPT Blood System for platelets and plasma, with ongoing development activities related to red blood cells. The company’s revenue model is largely recurring, driven by consumable disposable kits used in routine blood processing procedures, alongside sales or placements of associated illumination devices and service agreements. The company reports operations largely as a single operating segment focused on transfusion medicine technologies, though geographically it derives revenue from both U.S. and international markets.
Internationally, Cerus works through direct commercial operations and distribution partnerships across Europe, the Middle East, and parts of Asia-Pacific. The company has maintained collaborations with blood service organizations and government-supported healthcare systems that implement pathogen reduction protocols at national or regional levels. Cerus also relies on manufacturing and supply relationships for production and distribution of its technology platform, while retaining proprietary intellectual property tied to photochemical pathogen reduction processes involving amustaline and amotosalen compounds.
Strategic Position & Investments
Cerus’s strategic direction centers on expanding adoption of the INTERCEPT Blood System, advancing next-generation blood safety technologies, and increasing penetration in large institutional and government-supported blood collection systems. A significant area of investment has been the development of the INTERCEPT Red Blood Cell System, which remains under clinical and regulatory evaluation. The company has emphasized growth through regulatory expansion, broader reimbursement acceptance, and increased utilization among existing customers rather than through large-scale diversification.
The company has also invested in manufacturing scale, operational capacity, and clinical studies intended to support additional regulatory approvals and label expansions. Cerus maintains intellectual property portfolios related to pathogen inactivation and blood component processing technologies. While Cerus has historically entered collaborative and licensing arrangements with healthcare organizations and industry participants, publicly available sources do not identify major standalone subsidiaries or broad portfolio holdings comparable to diversified healthcare conglomerates. Data regarding future commercialization timelines for certain developmental programs remains subject to regulatory review and therefore cannot be conclusively verified beyond publicly disclosed guidance.
Geographic Footprint
Cerus is headquartered in Concord, California, and maintains commercial operations serving customers across North America, Europe, the Middle East, and selected international markets. The company’s strongest commercial presence historically has been in European countries where pathogen reduction adoption has been more established within national blood systems. The United States represents a major growth market following expanded regulatory approvals and increasing blood safety initiatives among hospitals and blood centers.
The company’s products are used in numerous countries through a combination of direct sales infrastructure and third-party distribution arrangements. Cerus has operational influence through partnerships with national blood agencies, regional healthcare authorities, and institutional transfusion centers. International expansion remains tied closely to local regulatory approvals, public health priorities, and procurement decisions made by centralized healthcare systems.
Leadership & Governance
Cerus was co-founded by biomedical entrepreneur Claes Glassell and scientist Laurence Corash, whose research contributed to the scientific foundation of the company’s pathogen reduction technologies. The company’s leadership strategy has consistently emphasized blood safety innovation, regulatory engagement, and expansion of global transfusion medicine standards through adoption of pathogen inactivation technologies.
Key executives include:
- William “Obi” Greenman – President and Chief Executive Officer
- Kevin D. Green – Chief Financial Officer
- Vivian Liu – Vice President, General Counsel and Corporate Secretary
- Richard J. Benjamin, M.D., Ph.D. – Chief Medical Officer
- Carol Moore – Vice President, Regulatory Affairs and Quality
Cerus leadership has publicly emphasized long-term commercialization of pathogen reduction as a standard component of transfusion safety infrastructure, with continued investment in clinical evidence generation, regulatory approvals, and operational scalability. Governance practices and executive disclosures are documented through SEC filings, including annual reports and proxy statements, alongside investor presentations and earnings materials.